The joint process, launched by MediSapiens and VEIL.AI, aims to address the key challenges in fully utilising data for the benefit of patients: access to data and combining data from several sources. The process ensures that valuable information is not lost during the anonymisation and that the anonymised and harmonised data is compatible with data from other sources. It also supports the growing need for high-quality clinical data from multiple sources for use with machine learning and AI-based applications, to support improved patient diagnostics and treatments.
“We regularly hear from clients the requirement and wish to use rich clinical data from multiple sources, yet they face challenges in combining these data sets because of the sensitivity and compatibility of these data sets. The MediSapiens-VEIL.AI process addresses those challenges in an innovative and cost-saving manner”, says Hans Garritzen, VP of Sales at MediSapiens.
As part of the launch of the joint process, the companies have created a white paper detailing the process and its advantages.
Future Clinical Trials project streamlines drug research
Both VEIL.AI and MediSapiens are also participating in an international Future Clinical Trials project, implemented in Finland and aiming to speed up drug research and increase safety. The project utilises artificial intelligence and streamlines drug research. If successful, the project will improve drug research practices worldwide.
Finland was chosen as the target country for the international project thanks to its high-quality health data and high-level technological know-how, among other reasons. The project is launched by the life science company Bayer. Participating in the project is a community of stakeholders specialising in health data science: in addition to MediSapiens and VEIL.AI, also DAIN Studios, Finnish Center for Artificial Intelligence (FCAI) and MedEngine.